Objective: Large cell neuroendocrine carcinoma of the lung are considered aggressive. However, reported prognoses are heterogeneous and the optimum treatment remains undefined. We retrospectively evaluated outcomes in a series of patients with a pathological diagnosis of Large cell. neuroendocrine lung carcinoma, who underwent lung resection. We also assessed the utility of chemotherapy in a small subgroup. Patients and methods: The clinical records of 144 consecutive patients were reviewed in a multicenter study. Survival times, assessed from the day of surgery until death or most recent follow-up, were estimated by the Kaplan-Meier method, and compared by the log rank test. Results: There were 117 men and 27 women of median age 63 years. Twelve wedge resections, 3 segmentectomies, 95 lobectomies, 7 bilobectomies and 24 pneumonectomies were performed. Induction chemotherapy was given in 21 and postoperative chemotherapy in 24. Pathologically, 73 (50%) were stage I, 29 (20%) stage II, 40 (28%) stage III and 2 stage IV. Postoperative mortality was 2.8% and morbidity 26%. Overall. 5-year survival was 42.5%: 52% for stage I, 59% for stage II and 20% for stage III (p = 0.001 log-rank test on Kaplan-Meier curves). A trend to better outcome was associated with preoperative or postoperative chemotherapy in stage I disease (p = 0.077) compared to no chemotherapy. The response rate to induction chemotherapy was 80% in the 15 patients with data available. Conclusion: large cell neuroendocrine carcinoma of the lung are confirmed as aggressive but are also chemosensitive. Our experience suggests that chemotherapy may improve prognosis in stage I disease.

Large cell neuroendocrine carcinoma of the lung: A retrospective analysis of 144 surgical cases / Veronesi, G; Morandi, Uliano; Alloisio, M; Terzi, A; Cardillo, G; Filosso, P; Rea, F; Facciolo, F; Pelosi, G; Gandini, S; Calabro, F; Casali, C; Marulli, G; Spaggiari, L.. - In: LUNG CANCER. - ISSN 0169-5002. - STAMPA. - 53:(2006), pp. 111-115. [10.1016/j.lungcan.2006.03.007]

Large cell neuroendocrine carcinoma of the lung: A retrospective analysis of 144 surgical cases

MORANDI, Uliano;
2006

Abstract

Objective: Large cell neuroendocrine carcinoma of the lung are considered aggressive. However, reported prognoses are heterogeneous and the optimum treatment remains undefined. We retrospectively evaluated outcomes in a series of patients with a pathological diagnosis of Large cell. neuroendocrine lung carcinoma, who underwent lung resection. We also assessed the utility of chemotherapy in a small subgroup. Patients and methods: The clinical records of 144 consecutive patients were reviewed in a multicenter study. Survival times, assessed from the day of surgery until death or most recent follow-up, were estimated by the Kaplan-Meier method, and compared by the log rank test. Results: There were 117 men and 27 women of median age 63 years. Twelve wedge resections, 3 segmentectomies, 95 lobectomies, 7 bilobectomies and 24 pneumonectomies were performed. Induction chemotherapy was given in 21 and postoperative chemotherapy in 24. Pathologically, 73 (50%) were stage I, 29 (20%) stage II, 40 (28%) stage III and 2 stage IV. Postoperative mortality was 2.8% and morbidity 26%. Overall. 5-year survival was 42.5%: 52% for stage I, 59% for stage II and 20% for stage III (p = 0.001 log-rank test on Kaplan-Meier curves). A trend to better outcome was associated with preoperative or postoperative chemotherapy in stage I disease (p = 0.077) compared to no chemotherapy. The response rate to induction chemotherapy was 80% in the 15 patients with data available. Conclusion: large cell neuroendocrine carcinoma of the lung are confirmed as aggressive but are also chemosensitive. Our experience suggests that chemotherapy may improve prognosis in stage I disease.
53
111
115
Large cell neuroendocrine carcinoma of the lung: A retrospective analysis of 144 surgical cases / Veronesi, G; Morandi, Uliano; Alloisio, M; Terzi, A; Cardillo, G; Filosso, P; Rea, F; Facciolo, F; Pelosi, G; Gandini, S; Calabro, F; Casali, C; Marulli, G; Spaggiari, L.. - In: LUNG CANCER. - ISSN 0169-5002. - STAMPA. - 53:(2006), pp. 111-115. [10.1016/j.lungcan.2006.03.007]
Veronesi, G; Morandi, Uliano; Alloisio, M; Terzi, A; Cardillo, G; Filosso, P; Rea, F; Facciolo, F; Pelosi, G; Gandini, S; Calabro, F; Casali, C; Marulli, G; Spaggiari, L.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/613016
Citazioni
  • ???jsp.display-item.citation.pmc??? 38
  • Scopus 125
  • ???jsp.display-item.citation.isi??? 105
social impact